ArticleOncogene2026
Midkine-activated TRPA1+ cancer-associated fibroblasts promote immunotherapy resistance in gastric cancer through a WNT5A-mediated treg circuit.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
Gastric cancer (GC) derives limited benefit from immune checkpoint blockade (ICB), in part due to stromal-mediated immune suppression. To investigate the underlying mechanisms, we performed single-cell RNA sequencing on 14 GC specimens from patients treated with neoadjuvant ICB. We identified a distinct subset of TRPA1+ cancer-associated fibroblasts (CAFs) maintained by tumor-derived midkine (MDK) through LEF1-dependent transcription under ICB pressure. These TRPA1+ CAFs drive immunosuppression by secreting WNT5A, which polarizes SPP1+ macrophages and subsequently promotes the accumulation of CD25 + FOXP3+ regulatory T cells (Tregs) in the tumor microenvironment. Disrupting this stromal-myeloid-lymphoid axis via WNT5A inhibition or SPP1+ macrophage depletion reduced Treg infiltration and enhanced the antitumor efficacy of anti-PD-L1 therapy in vivo. Our study unveils an MDK-TRPA1 + CAF-mediated mechanism of ICB resistance in GC and highlights the WNT5A-SPP1+ macrophage pathway as a promising target to overcome immunotherapy resistance.
Indexed as
Identifiers
42547554What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.